Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_4
4
40%
Ph phase_3
4
40%
Ph phase_1
1
10%
Ph phase_2
1
10%

Phase Distribution

1

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
4(40.0%)
Phase 4Post-market surveillance
4(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(7)
Terminated(1)
Other(2)

Detailed Status

Completed7
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 34 (40.0%)
Phase 44 (40.0%)

Trials by Status

completed770%
unknown220%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

NCT03018041
completedphase_4

Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids

NCT00760513
unknownphase_1

Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

NCT03438955
completedphase_3

OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease

NCT01367145
completedphase_3

An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients

NCT01725646
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03018041Phase 3

The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

Completed
NCT00760513Phase 4

Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids

Completed
NCT03438955Phase 1

Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

Unknown
NCT01367145Phase 3

OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease

Completed
NCT01725646Phase 3

An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients

Completed
NCT01277237Phase 3

The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease

Completed
NCT00149409Phase 2

Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure

Completed
NCT00437099Phase 4

Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder

Unknown
NCT00328536Phase 4

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

Completed
NCT00598910Phase 4

Effect of Omacor on Triglycerides in HIV Infected Subjects

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
10